{"name":"Erasca, Inc.","slug":"erasca","ticker":"ERAS","exchange":"NASDAQ","domain":"erasca.com","description":"Erasca, Inc. is a precision oncology company focused on developing therapies for cancer. The company's pipeline includes several promising candidates, including tucationumab, a PD-1 inhibitor. Erasca has established a strong presence in the biotech sector, with a growing portfolio of assets and a talented team of scientists and clinicians. As a leader in precision oncology, Erasca is well-positioned to capitalize on the growing demand for targeted therapies.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Jonathan Lim","sector":"Precision Oncology / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$650M","metrics":{"revenue":15000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Tucationumab patent cliff ($0.0B at risk)","drug":"Tucationumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ERAS-601","genericName":"ERAS-601","slug":"eras-601","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ERAS-601","genericName":"ERAS-601","slug":"eras-601","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Erasca Announces FDA Clearance of Investigational New Drug (IND) Application for EQRx-202","summary":"Erasca, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for EQRx-202, a novel, orally administered, small molecule inhibitor of the TIGIT/PVRIG axis.","drugName":"EQRx-202","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Erasca Reports Third Quarter 2023 Financial Results","summary":"Erasca, Inc. reported its financial results for the third quarter of 2023, highlighting a strong cash position and significant progress in its pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Erasca Announces Collaboration with Merck KGaA to Develop Novel Cancer Therapies","summary":"Erasca, Inc. announced a collaboration with Merck KGaA to develop novel cancer therapies, further expanding its pipeline and capabilities.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNa2c5RWVob0UwcGplR2dISkJpNldIUlJNdDRxRVU3aWdFNU4wcFVXcGd0SUVGa2QxdGJfdzNkbmp1Nlk5aVNZWlBWZE9MalY5UXhiaHFFTHljblpNMGdSejd5SUhSaFNTYjRqSVVaems0S3N6TU5jZ0pFWjFrcHBJbE5RbGtDUzBnaEZGeWN5Z1Q5MFlXRkNacDMwUV9tTVNPUnM3a21SRlFsajJaUVp6OFhwMWFrRWdWTFZDQlR2U2E4V01XLVhZVnZhd2tmeUp6QWZjdkh2azZodk9EdktCR1VVUWJFa0hLSU1OVG1TdWJxZHBaTWhNN2o1VF8yYjBCV2VuQWpXOGQ?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga","headline":"Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"deal","source":"simplywall.st","summary":"How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors - simplywall.st","headline":"How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOVWhzQ2lGLUV4WVVkWlRBUUwyUlpoTmh3WHpkeXVscEVLdzNmY1BMSmtETFBGSFpQM0FEYjM3anBfcl9Eb2NLb1lralBZb3Z2R1lwLWJjOFBLdVFBUmhCZjR2cjhpYmhuU0xFUnlhMDlCMkZQNS0zc0NqemNtdzhPWE8zdmZiSUduQkZXWGt5ZEVtV0NHNTZqOFVaWDJNYzdvMkF0Q3czUmFrelNRcktJc2tlMm5EbGNDNVptMFlQbw?oc=5","date":"2026-03-06","type":"deal","source":"TradingView","summary":"TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS - TradingView","headline":"TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9pc0wxdFd3MjZPeVY1cnJHTk9HQ0FhZ2l4Y1hRX3o1NEF6MlhHb3dPSnpRMkdUQVIxQjJXMHFJVTlOZE00QjFWNzZ6WlJ0TWlFSTFTekNTdm9rY1ZESEZ1Zk5MaXlSbkZUc2FiLWZyRmZKU3c?oc=5","date":"2026-02-28","type":"pipeline","source":"Finviz","summary":"Erasca, Inc. (ERAS): A Bull Case Theory - Finviz","headline":"Erasca, Inc. (ERAS): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNM2tTcHdxbG12T2lva1NIbWFSYS1GWEhTVFU0dGthUElvR2RMbU1SSGZxdkZUY25NTVdxT1I3anhqVWM4UzlLeXh1U3JUSDR6dXR1ZGtEMEhTbW9nMXY0UVQ3R0xiWXE2LU93eHhkNlg1d25lQUlzVXpvcU1saVJHaWNXRHNsaEJibmxNSjJtdWpqZ0sxVXhWNXpQeFhOYnZPTldrRXQwamZmV2dBaEhYYV9oSC13WlUyNU5JQ29jejROWEVIa1JRR1h3MnhadDA3X0NZMFJKQ250aHl2QVg2SDdZc2hCNEk?oc=5","date":"2026-01-26","type":"pipeline","source":"Benzinga","summary":"Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga","headline":"Revolution Medicines, Erasca And Other Big Stocks Moving Lower In Monday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPU2lwQmdCLUJlbGVVblEtdFdQWWpWSmtUeGFrbUlBRmNtMWVrXzVvSTVJMXhvRjhKRU1pRk94SUZsa1U5VmpnTGM1aUl5NGhzYnpCcHVMRU9VUlpQakpjT21qajRSQWpKbVh3UW1JV0NWVVRka1g0aTc1MllGYWlkTEd6VDBLX1ROVllqdWVQdzdDRGtzUzQ1b3Q4QUdBcXVnUlVaWVRkblZnTy0tNDNwX0YzRUMwZXlwZC1zVU9EV0RiZw?oc=5","date":"2025-12-11","type":"pipeline","source":"PR Newswire","summary":"Platform Technologies Drive $211B Surge in Precision Cancer Treatment - PR Newswire","headline":"Platform Technologies Drive $211B Surge in Precision Cancer Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9xMExKS0dZZWNNeEtPUV9iUi1BZW92VkxkUUVjQmt1STJCejV5a0NBa3YwOS1CYXJvamFSZUh1dUJWbnVnWHBkRjJ0bm5tdXluZEhnT3RtSDY4Yy1MZEwxT1otRUxmQ2doVS1BZ2otSjBWWWh0NFY3YTE0aw?oc=5","date":"2025-05-14","type":"trial","source":"Oncology Pipeline","summary":"Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Erasca enters its pan-RAS era | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQUWllNnYydzNxZWR2ZkR5RkJxZHB0d0N4LUpqOHRvYWJtclVvUlBud2g4SmdaUzV5eDFuWXJManlfSVhpU2ZGczdLeUQzdDdrRVF3TDNTNGNqZk9PQlZEcDVuLVlnQzl2TnBNaW9hcGZYWV9GWVBZTDdQRm96c0twUXhpcUtQWGRBQ3dMY1FKWXAwRTF2NXVGVi01RDVUZGlPaGhONFlValRaU0J6?oc=5","date":"2025-05-13","type":"trial","source":"Fierce Biotech","summary":"Erasca enters another era, seeks partner for phase 3 ex-Novartis asset - Fierce Biotech","headline":"Erasca enters another era, seeks partner for phase 3 ex-Novartis asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE03V1I2c2NCemRrMzFzVWpJdjZIYWZkbEVEQldacnR2b0NwTkRZbFI3M2t3S1I1bDRRSUExLTVQWXRGWU04VEpUZjRjZHlGc1ZwSWRr?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"ERAS Stock Price, News & Analysis - Stock Titan","headline":"ERAS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNbHFuWXQyN1Q1WDg3WjU1c0ZQWTl4YkdjanJBMmZJd3BzOTVlNUk0eUQyall0QWU0bEhuSnhlaTBpWXRBUkI0UlB1X29iUkFBZGQwZjRFQlFFaTdSTDBMSjFoLTFLUG9KMEtKSzJnWnNoS0prTGxhRDBENkk5QUpiQjBNYktpU0Iya2NxcndvbTZfUFhRSXJ2bWJLc096OExKWkI5U0Q5V3FsejE5QjRPeS1pbk5MOERuVmFlcA?oc=5","date":"2024-05-17","type":"pipeline","source":"Pharmaceutical Technology","summary":"Erasca trims workforce and pipeline to focus on KRAS and molecular glues - Pharmaceutical Technology","headline":"Erasca trims workforce and pipeline to focus on KRAS and molecular glues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5NOUt0bHgwbzFueHFTTWF0WC1Zb2o4Q2ZxVExLQXpPdE9ES25vWnZZQl9jb24tcFpRdEwyUzQ1VHN2ZnZWdFAzSEFqbGtrXzBSQVJ5OGxYLWZYaUlkVU15VWc3MGx2dkhsX2VGNlppejRpLVU?oc=5","date":"2024-05-17","type":"trial","source":"Oncology Pipeline","summary":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Erasca doubles down on RAS | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBFTVdEeEJtaFQzMG1vS3FaMDNEdUM2THNPR0xHYnhvRGg3YVBDSkJ6Z2pqSFF1UGRqU1NzVDZBUXhuekxUbVlJX2RtRGpyVHpF?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Tucationumab","drugSlug":"tucationumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Precision Oncology"],"financials":null,"yahoo":null}